Future directions for resuscitation research. IV. Innovative advanced life support pharmacology

Charles Brown, Lars Wiklund, Gad Bar-Joseph, Brian Miller, Nicholas Bircher, Norman Paradis, James Menegazzi, Martin Von Planta, George Kramer, Sven Erik Gisvold, Peter Safar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The topics discussed in this session include a partial review of laboratory and clinical studies examining the effects of adrenergic agonists on restoration of spontaneous circulation after cardiac arrest, the effects of varying doses of epinephrine, and the effects of novel vasopressors, buffer agents (NaHCO3, THAM, 'Carbicarb') and anti-arrhythmics (lidocaine, bretylium; amiodarone) in refractory ventricular fibrillation. Novel therapeutic approaches include titrating electric countershocks against electrocardiographic power spectra and of preceding the first countershocks with single or multiple drug treatments. These approaches need to be investigated further in controlled animal and patient studies. Epidemiologic data from randomized clinical outcome studies can give clues, but cannot document pharmacologic mechanisms in the dynamically changing events during attempts to achieve restoration of spontaneous circulation from prolonged cardiac arrest. Also, rapid drug administration by the intraosseous route was compared with intratracheal and intravenous (i.v.) drug administration. Many studies on the above treatments have yielded conflicting results because of differences between healthy hearts of animals and sick hearts of patients, differences in arrest (no-flow) times and cardiopulmonary resuscitation (CPR) (low-flow) times, different pharmacokinetics, different dose/response requirements, and different timing of drug administration during low-flow CPR versus during spontaneous circulation. The need to stabilize normotension and prevent rearrest by titrated novel drug administration, once spontaneous circulation has been restored, requires research. Most of the above topics require some re-evaluation in:clinically realistic animal models and in cardiac arrest patients, especially by titration of old and new drug treatments against variables that can be monitored continuously during resuscitation.

Original languageEnglish (US)
Pages (from-to)163-177
Number of pages15
JournalResuscitation
Volume33
Issue number2
DOIs
StatePublished - Dec 1996
Externally publishedYes

Fingerprint

Resuscitation
Pharmacology
Heart Arrest
Research
Pharmaceutical Preparations
Cardiopulmonary Resuscitation
Drug Administration Routes
Adrenergic Agonists
Electric Countershock
Amiodarone
Anti-Arrhythmia Agents
Vasoconstrictor Agents
Ventricular Fibrillation
Therapeutics
Lidocaine
Intravenous Administration
Epinephrine
Buffers
Animal Models
Pharmacokinetics

Keywords

  • Adrenergic agonists
  • Anti-arrhythmia agents
  • Buffers
  • Cardiopulmonary resuscitation
  • Clinical trials
  • Defibrillation
  • Electric countershock
  • Electrocardiography
  • Intraosseous medication
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Nursing(all)

Cite this

Brown, C., Wiklund, L., Bar-Joseph, G., Miller, B., Bircher, N., Paradis, N., ... Safar, P. (1996). Future directions for resuscitation research. IV. Innovative advanced life support pharmacology. Resuscitation, 33(2), 163-177. https://doi.org/10.1016/S0300-9572(96)01017-9

Future directions for resuscitation research. IV. Innovative advanced life support pharmacology. / Brown, Charles; Wiklund, Lars; Bar-Joseph, Gad; Miller, Brian; Bircher, Nicholas; Paradis, Norman; Menegazzi, James; Von Planta, Martin; Kramer, George; Gisvold, Sven Erik; Safar, Peter.

In: Resuscitation, Vol. 33, No. 2, 12.1996, p. 163-177.

Research output: Contribution to journalArticle

Brown, C, Wiklund, L, Bar-Joseph, G, Miller, B, Bircher, N, Paradis, N, Menegazzi, J, Von Planta, M, Kramer, G, Gisvold, SE & Safar, P 1996, 'Future directions for resuscitation research. IV. Innovative advanced life support pharmacology', Resuscitation, vol. 33, no. 2, pp. 163-177. https://doi.org/10.1016/S0300-9572(96)01017-9
Brown, Charles ; Wiklund, Lars ; Bar-Joseph, Gad ; Miller, Brian ; Bircher, Nicholas ; Paradis, Norman ; Menegazzi, James ; Von Planta, Martin ; Kramer, George ; Gisvold, Sven Erik ; Safar, Peter. / Future directions for resuscitation research. IV. Innovative advanced life support pharmacology. In: Resuscitation. 1996 ; Vol. 33, No. 2. pp. 163-177.
@article{d28fe2baafe84148b28be465a47a8c97,
title = "Future directions for resuscitation research. IV. Innovative advanced life support pharmacology",
abstract = "The topics discussed in this session include a partial review of laboratory and clinical studies examining the effects of adrenergic agonists on restoration of spontaneous circulation after cardiac arrest, the effects of varying doses of epinephrine, and the effects of novel vasopressors, buffer agents (NaHCO3, THAM, 'Carbicarb') and anti-arrhythmics (lidocaine, bretylium; amiodarone) in refractory ventricular fibrillation. Novel therapeutic approaches include titrating electric countershocks against electrocardiographic power spectra and of preceding the first countershocks with single or multiple drug treatments. These approaches need to be investigated further in controlled animal and patient studies. Epidemiologic data from randomized clinical outcome studies can give clues, but cannot document pharmacologic mechanisms in the dynamically changing events during attempts to achieve restoration of spontaneous circulation from prolonged cardiac arrest. Also, rapid drug administration by the intraosseous route was compared with intratracheal and intravenous (i.v.) drug administration. Many studies on the above treatments have yielded conflicting results because of differences between healthy hearts of animals and sick hearts of patients, differences in arrest (no-flow) times and cardiopulmonary resuscitation (CPR) (low-flow) times, different pharmacokinetics, different dose/response requirements, and different timing of drug administration during low-flow CPR versus during spontaneous circulation. The need to stabilize normotension and prevent rearrest by titrated novel drug administration, once spontaneous circulation has been restored, requires research. Most of the above topics require some re-evaluation in:clinically realistic animal models and in cardiac arrest patients, especially by titration of old and new drug treatments against variables that can be monitored continuously during resuscitation.",
keywords = "Adrenergic agonists, Anti-arrhythmia agents, Buffers, Cardiopulmonary resuscitation, Clinical trials, Defibrillation, Electric countershock, Electrocardiography, Intraosseous medication, Ventricular fibrillation",
author = "Charles Brown and Lars Wiklund and Gad Bar-Joseph and Brian Miller and Nicholas Bircher and Norman Paradis and James Menegazzi and {Von Planta}, Martin and George Kramer and Gisvold, {Sven Erik} and Peter Safar",
year = "1996",
month = "12",
doi = "10.1016/S0300-9572(96)01017-9",
language = "English (US)",
volume = "33",
pages = "163--177",
journal = "Resuscitation",
issn = "0300-9572",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Future directions for resuscitation research. IV. Innovative advanced life support pharmacology

AU - Brown, Charles

AU - Wiklund, Lars

AU - Bar-Joseph, Gad

AU - Miller, Brian

AU - Bircher, Nicholas

AU - Paradis, Norman

AU - Menegazzi, James

AU - Von Planta, Martin

AU - Kramer, George

AU - Gisvold, Sven Erik

AU - Safar, Peter

PY - 1996/12

Y1 - 1996/12

N2 - The topics discussed in this session include a partial review of laboratory and clinical studies examining the effects of adrenergic agonists on restoration of spontaneous circulation after cardiac arrest, the effects of varying doses of epinephrine, and the effects of novel vasopressors, buffer agents (NaHCO3, THAM, 'Carbicarb') and anti-arrhythmics (lidocaine, bretylium; amiodarone) in refractory ventricular fibrillation. Novel therapeutic approaches include titrating electric countershocks against electrocardiographic power spectra and of preceding the first countershocks with single or multiple drug treatments. These approaches need to be investigated further in controlled animal and patient studies. Epidemiologic data from randomized clinical outcome studies can give clues, but cannot document pharmacologic mechanisms in the dynamically changing events during attempts to achieve restoration of spontaneous circulation from prolonged cardiac arrest. Also, rapid drug administration by the intraosseous route was compared with intratracheal and intravenous (i.v.) drug administration. Many studies on the above treatments have yielded conflicting results because of differences between healthy hearts of animals and sick hearts of patients, differences in arrest (no-flow) times and cardiopulmonary resuscitation (CPR) (low-flow) times, different pharmacokinetics, different dose/response requirements, and different timing of drug administration during low-flow CPR versus during spontaneous circulation. The need to stabilize normotension and prevent rearrest by titrated novel drug administration, once spontaneous circulation has been restored, requires research. Most of the above topics require some re-evaluation in:clinically realistic animal models and in cardiac arrest patients, especially by titration of old and new drug treatments against variables that can be monitored continuously during resuscitation.

AB - The topics discussed in this session include a partial review of laboratory and clinical studies examining the effects of adrenergic agonists on restoration of spontaneous circulation after cardiac arrest, the effects of varying doses of epinephrine, and the effects of novel vasopressors, buffer agents (NaHCO3, THAM, 'Carbicarb') and anti-arrhythmics (lidocaine, bretylium; amiodarone) in refractory ventricular fibrillation. Novel therapeutic approaches include titrating electric countershocks against electrocardiographic power spectra and of preceding the first countershocks with single or multiple drug treatments. These approaches need to be investigated further in controlled animal and patient studies. Epidemiologic data from randomized clinical outcome studies can give clues, but cannot document pharmacologic mechanisms in the dynamically changing events during attempts to achieve restoration of spontaneous circulation from prolonged cardiac arrest. Also, rapid drug administration by the intraosseous route was compared with intratracheal and intravenous (i.v.) drug administration. Many studies on the above treatments have yielded conflicting results because of differences between healthy hearts of animals and sick hearts of patients, differences in arrest (no-flow) times and cardiopulmonary resuscitation (CPR) (low-flow) times, different pharmacokinetics, different dose/response requirements, and different timing of drug administration during low-flow CPR versus during spontaneous circulation. The need to stabilize normotension and prevent rearrest by titrated novel drug administration, once spontaneous circulation has been restored, requires research. Most of the above topics require some re-evaluation in:clinically realistic animal models and in cardiac arrest patients, especially by titration of old and new drug treatments against variables that can be monitored continuously during resuscitation.

KW - Adrenergic agonists

KW - Anti-arrhythmia agents

KW - Buffers

KW - Cardiopulmonary resuscitation

KW - Clinical trials

KW - Defibrillation

KW - Electric countershock

KW - Electrocardiography

KW - Intraosseous medication

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=17344382792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344382792&partnerID=8YFLogxK

U2 - 10.1016/S0300-9572(96)01017-9

DO - 10.1016/S0300-9572(96)01017-9

M3 - Article

VL - 33

SP - 163

EP - 177

JO - Resuscitation

JF - Resuscitation

SN - 0300-9572

IS - 2

ER -